Research Triangle Park, N.C. – November 17, 2008 – Catalent’s Respiratory, Analytical and Biotechnology Group will be well represented at this year’s American Association of Pharmaceutical Scientists (AAPS) Annual Meeting. A number of Catalent team members from its Research Triangle Park, N.C., San Diego, C.A. and Middleton, W.I. sites will lead scientific poster presentations and a round table discussion as part of the conference proceedings. The 2008 AAPS Annual Meeting and Exposition takes place in Atlanta, G.A., November 16-20, 2008. Catalent is a corporate sponsor of the event, providing a grant to fund roundtable discussions and symposia.
On Thursday, November 20, Dr. Lanying Q. Hatcher will present a scientific poster titled “Disintegration Testing as an Acceptable Alternative to Dissolution Testing for Fast Dissolve Formulations.” The poster’s authors include: Dr. Lanying Q. Hatcher, a scientist in Catalent’s Stability and Analytical Services group; Christopher L. Wittum, a scientist in Catalent’s Product Participation group; and Stephen P. Mayock, senior manager in Catalent’s Stability and Analytical Services group. All three authors are based in Catalent’s Research Triangle Park location. Poster abstract: To use USP Apparatus IV to demonstrate orthogonally that disintegration can be an acceptable alternative to dissolution testing for fast dissolve (oral disintegrating) formulations. Also on Thursday, Stephen P. Mayock will be leading the “In Vitro Release and Dissolution Testing” focus group as the focus group chair.
Additionally, on Thursday, November 20, Charlotte Carroll, a senior scientist at Catalent, will present a scientific poster titled “Determination of APR Salt/Acid Ratios in a Soft-Gel Formulation by Quantitative 13C NMR Spectroscopy.” (Poster R6012) Carroll manages Catalent’s Organic Spectroscopy group, which includes mass spectrometry and spectroscopy techniques such as NMR (small- and bio-molecular), UV and FTIR, as well as thermal analysis (DSC, TGA). Carroll’s co-authors include Tom Feinberg, Catalent’s director of structural chemistry services. Poster abstract: A drug product was suspected of violating a customer’s patent that specified the ratio of API to an acidic counter-ion. Nuclear magnetic resonance (NMR) spectroscopy was used to determine the ratio of the API to the counter-ion. 13C NMR data was acquired under conditions that allowed for quantitation through relative integration, as well as through a correlation in chemical shift variance.
About Catalent
Headquartered in Somerset, New Jersey, Catalent is one of the leading providers of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer health companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,500 at more than 30 facilities worldwide and generates more than $1.8 billion of annual revenue. For more information, visit www.catalent.com.
